Q-omics provides the consensus-scored IDH3A profile across patient tissues and cancer cell-line models. IDH3A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IDH3A is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, IDH3A protein abundance shows 25,517 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where IDH3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IDH3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IDH3A survival associations across molecular data types. IDH3A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IDH3A RNA expression–survival associations across cancer types. High IDH3A expression shows unfavorable associations in UVM, KIRP, BLCA and LAML, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IDH3A RNA expression.
This table summarizes IDH3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IDH3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IDH3A shows lower tumor expression in COAD, THCA, KIRC and READ and higher tumor expression in LUSC and CHOL. The COAD box plot shows higher IDH3A RNA expression in normal versus tumor tissue (log2 FC = −0.660, t-test p < 0.001).
This table shows molecular features associated with IDH3A in patient tissues and cancer cell lines. In patient samples, IDH3A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IDH3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
